Clinical Research Directory
Browse clinical research sites, groups, and studies.
Semaglutide's Weight Loss Effects in Obesity
Sponsor: Beijing Chao Yang Hospital
Summary
This is a non-randomized, concurrent, parallel-controlled clinical trial. The objective of this trial is to determine the relationship between weight loss responsiveness to semaglutide in obese patients and their gut microbiota.
Official title: Clinical Assessment of Semaglutide-Induced Weight Reduction in Obese Populations
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2025-02-20
Completion Date
2027-12-31
Last Updated
2025-02-13
Healthy Volunteers
No
Conditions
Interventions
Semaglutide Subcutaneous Injection
All subjects received subcutaneous injections of semaglutide over a 28-week treatment period, which included an initial 16-week dose-escalation phase. The escalation protocol began with a starting dose of 0.25 mg administered once weekly. Every 4 weeks, the dose was gradually increased in a stepwise manner to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each administered once weekly.